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Abstract
Objectives: To analyse survival rate after 24 months in consecutive patients with a diagnosis of
PE as well as associated factors.
Methods: Prospective cohort study during a follow-up period of two years in a series of conse-
cutive patients with PE.
Results: During the follow-up period, 34 out of 148 patients died (23%). Factors independently
associated with reduced survival rate were: creatinine levels > 2 (OR, 8.8; 95% CI, 1.1 - 70.87),
previous neoplasm (OR, 8.8; 95% CI, 3.69 - 20.98), dementia (OR, 6.85; 95% CI, 2.1 - 22.33)
and dyslipidemia (OR, 5.07; 95% CI, 1.92 - 13.44). Forty four percent of the patients with
dyslipidemia died vs. 20.8% of patients without this condition.
Conclusions: In our study dyslipidemia shows as a long-term negative prognostic marker for
survival in patients with EP.
© 2011 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L. All rights
reserved.PALAVRAS-CHAVE Dislipidemia como um marcador de longo prazo para a sobrevivência na embolia
Dislipidemia; pulmonar
Doenc¸as metabólicas
lipídicas; Resumo
Objetivos: Analisar a taxa de sobrevivência após 24 meses, em pacientes consecutivos com
diagnóstico de PE, bem como fatores associados.
∗ Autor para correspondencia.
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Embolia pulmonar;
Análise de
sobrevivência;
Tromboembolismo
venoso
Métodos: Estudo prospectivo durante um período de seguimento de dois anos em uma série
consecutiva de pacientes com PE.
Resultados: Durante o período de acompanhamento, 34 dos 148 pacientes morreram (23%).
Fatores independentemente associados à reduzida taxa de sobrevivência foram: os níveis de
creatinina> 2 (OR, 8,8; 95% CI, 1,1-70,87), neoplasia anterior (OR, 8,8; IC 95%, 3,69-20,98),
demência (OR, 6,85; 95% CI, 2,1-22,33) e dislipidemia (OR, 5,07; IC 95%, 1,92-13,44). Quarenta
e quatro por cento dos pacientes com dislipidemia morreram contra 20,8% dos pacientes sem
essa condic¸ão.
Conclusões: No nosso estudo, a dislipidemia mostra-se um marcador prognóstico negativo de
longo prazo na sobrevida de pacientes com EP.
© 2011 Sociedade Portuguesa de Pneumologia. Publicado por Elsevier España, S.L. Todos os
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ntroduction
enous thromboembolic disease (VTE) is a complex condition
ith a multifactor aetiology in which both the clinical history
f the patient and the genetic and environmental factors
lay a role.
Survival rate after VTE is worse than expected and it is
ven worse after pulmonary embolism (PE) than after deep
enous thrombosis (DVT) alone1. Mortality during follow-up
f patients with VTE has been the topic of several research
tudies and it ranges from 12.5%2 to 37%3. VTE recurrence is
o often that, about 30% of patients, present recurrences in
he following 10 years4.
Patients with VTE show several variables associated to a
ecreased survival rate. From a clinical point of view, it is
nteresting to which those aspects can be treated.
Patients with non treated dyslipidemia have a global
ortality rate a year of 9.7%5. As shown by several double-
lind placebo-controlled studies, the use of statins to
educe cholesterol levels signiﬁcantly decrease cardiovas-
ular risk6. Lower levels of cholesterol achieved by the
dministration of statins may reduce the incidence of ictus
n high risk populations and in patients with ictus or transient
schemic attack7.
Although we have found some studies which associate
yslipidemia with a higher risk of VTE8—12, none of these
orks has documented the prognostic role dyslipidemia may
lay in this type of patients.
In this paper, we present a long-term study of a series
f consecutive patients diagnosed with PE aiming to analyse
he main complications of such condition and their distribu-
ion in time and to establish the factors associated with a
ower survival rate.
aterial and methods
tudy design
rospective cohort study with a follow-up period of two
ears.
atientse analysed a cohort of consecutive patients diagnosed with
E from February 2003 through September 2004 at the Uni-
ersity Hospital Virgen del Rocío in Seville.
m
d
c
tethods
e considered as diagnostic criteria for PE: 1) high pro-
ability ventilation/perfusion lung scan, 2) intermediate or
ow probability ventilation/perfusion lung scan with signs
uggestive of arterial thrombosis as revealed by pulmonary
ngiography with or without signs of venous thrombosis in
ower limbs through ultrasound scan or venography. 3) Intra-
uminal ﬁlling defect observed in pulmonary angiography or
onsecutive sections of the vessels or more than 2.5mm in
iameter as revealed by pulmonary angiography. 4) Intra-
uminal ﬁlling defect in segmentary branches or in more
roximal branches as observed in helical CT scan.
ata collection strategy during the initial PE episode
atients were enrolled in the study through periodical visits
o the Emergency Unit, Internal Medicine Unit, Pneumology,
uclear Medicine and Radiology Units. A series of variables
ere noted down in a form designed for the purpose and
ere subsequently converted into computer format. Peri-
dical visit were made to the units where the patients were
dmitted in order to conﬁrm the correct completion of the
orm. We also revised in the Computer System for the Man-
gement of Clinical and Analytical Documentation (SIDCA)
Sistema Informático de Documentación Clínica y Analítica)
he list of patients with the EP code (CIE9) throughout the
tudy period. This work has been approved for Ethical Com-
ittee in our hospital.
The variables collected during the acute episode were
ivided into: epidemiological data (gender and age), risk
actors (family history of VTE, hormone therapy, previous
rauma, previous surgery, previous neoplasm (except for
on-melanoma skin cancer), baseline disease (previous his-
ory of VTE, arterial hypertension, congestive heart failure,
cute coronary syndrome, respiratory insufﬁciency, chronic
irway obstruction, acute cerebrovascular accident, demen-
ia, dyslipidemia and varicose syndrome) and prognostic and
linical characteristics (shock rate, partial oxygen pressure,
eart rate, systolic arterial tension, creatinine). Dyslipi-
emia was deﬁned as: hypertriglyceremia > 150mg/dL (1.69
mol/L) or HDL cholesterol (high-density lipoprotein) <
0mg/dL, (1.04 mmol/L) in males and < 50mg/dL (1.29
mol/L) in females. Congestive heart insufﬁciency was
eﬁned taking into account the NYHA functional class I-IV
lassiﬁcation. Dementia was deﬁned according to DSM-IV cri-
eria (memory impairment and at least one of the following
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Table 1 Variables associated to less survival rate
Variable Survive Die Relative Risk CI 95% p
Demographic characteristics
Males 55 (74.3%) 19 (25.7%) 1.30 0.66-2.57 0.44 (NS)
Age >70 yrs 52 (78.8%) 14 (21.2%) 0.85 0.43-1.69 0.65 (NS)
Risk factors
Hormonal therapy 16 (72.7%) 6 (27.3%) 1.20 0.50-2.90 0.68 (NS)
Trauma 13 (92.9%) 1 (7.1%) 2.52 0.03-1.84 0.17 (NS)
Surgery 31 (83.8%) 6 (16.2%) 0.61 0.25-1.48 0.27 (NS)
Previous neoplasm 14 (45.2%) 17 (54.8%) 5.07 2.58-9.96 0.000a
Baseline disease
Previous history of VTE 19 (86.4%) 3 (13.6%) 0.54 0.17-1.77 0.31 (NS)
Hypertension 49 (73.1%) 18 (26.9%) 1.38 0.70-2.70 0.35 (NS)
CHF 19 (73.1%) 7 (26.9%) 1.16 0.51-2.67 0.72 (NS)
ACS 10 (58.8%) 7 (41.2%) 2.16 0.94-4.97 0.07 (NS)
Chronic air-ﬂow obstruction 13 (65%) 7 (35%) 1.74 0.76-4.00 0.19(NS)
Asthma 10 (90.9%) 1 (9.1%) 0.36 0.05-2.62 0.31 (NS)
ACVA 15 (75%) 5 (25%) 1.10 0.43-2.85 0.84 (NS)
Dementia 4 (50%) 4 (50%) 3.15 1.11-8.97 0.03a
Dislypidemia 10 (55.6%) 8 (44.4%) 2.64 1.19-5.3 0.02a
Varicose syndrome 23 (88.5%) 3 (11.5%) 0.42 0.13-1.38 0.15 (NS)
Prognostic and evolutive characteristics
Shock rate ≥1 21 (72.4%) 1.29 0.58-2.85 0.53 (NS)
pO2 < 60 mmHg 25 (73.5%) 9 (26.5%) 1.01 0.50-2.43 0.82 (NS)
HR > 90 spm 74 (77.9%) 21 (22.1%) 0.87 0.44-1.74 0.70 (NS)
Systolic arterial pressure <100 mmHg 17 (77.3%) 5 (22.7%) 1.00 0.39-2.57 0.99 (NS)
Creatinine >2 mg/dL 1 (33.3%) 2 (66.7%) 6.59 1.57-27.70 0.01a
CI: Conﬁdence interval; VTE: Venous thromboembolic disease; CHF: Congestive heart failure; ACS: Acute coronary syndrome; ACVA:
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a Variables associated to lower survival at two years according t
cognitive alterations: aphasia, apraxia, agnosia, alteration
of cognitive functions. Also, these factors must be intense
enough to interfere with the occupational or social activi-
ties of the patients. The alterations indicate a deterioration
of such functions in comparison to the previous situation of
the patient. These symptoms are not exclusive of an embar-
rassment state.
Follow up of patients: In order to analyse survival rates
and long term complications we followed up all patients who
did not die during admission.
All patients were followed up in a monographic visit of
thromboembolic disease at months 1, 3, 6, 12, 18 and 24. We
noted down the date and cause of death of all the patients
who died during the follow-up period.
Strategy to capture losses was divided into: 1) tele-
phone contact with the patients who did not attend the
follow-up visits, 2) Computer System for the Management of
Clinical and Analytical Documentation (SIDCA) of the Univer-
sity Hospital Virgen del Rocío to identify episodes requiring
admission or referral to other units, 3) Review of clinical
histories.
Statistical analysisIn the statistical analysis of the results obtained we indi-
cate both absolute and relative frequency for qualitative
variables, and mean and standard deviation for quantitative
p
(
art rate; p: p < 0.05 is considered as statistically signiﬁcant.
ltivariate analysis.
ariables. In case of asymmetrical distribution of the varia-
les, we analysed median values and interquartile range. We
ompared the groups (deceased and non deceased) using
he chi-square test (qualitative variables) considering a p
alue < 0.05 as statistically signiﬁcant. The comparison of
ime free from episodes has been performed by means of
he Kaplan-Meier test together with the log rank test and
ultivariate analysis in order to control possible confusing
ariables, according to the Cox regression model.
esults
he sample obtained in our cohort was 148 patients. Half
f the patients (n = 74) were male. Mean age of patients
as 64.2± 17.2 yrs. During the two-year follow-up period
4 patients died (23%). The causes of death were: can-
er (n = 20), acute coronary syndrome (n = 6), sudden death
ith dyspnoea (n = 4), major bleeding in the digestive
ract (n = 1), non hemorrhagic acute cerebrovascular stroke
n = 1) and unknown causes (n = 2). Accumulated mortality
ate reached 19.2% after one year and 29.6% after two
ears.
Patients (272 patients/year) were followed up for a
eriod of 24± 23.8 (median± range). 73.6% of the sample
23% dead and 3.4% lost) was followed up for 24 months.
Table (table 1) shows those variables whose possible
ssociation with less survival rate at two years has been
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pigure 1 Cumulative survival in patients with and without
yslipidemia.
nalysed. Independent variables associated to less survival
ate were: creatinine levels > 2 (OR, 8.8; 95% CI, 1.1 —
0.87), previous neoplasm (OR, 8.8; 95% CI, 3.69 — 20.98),
ementia (OR, 6.85; 95% CI, 2.1 — 22.33) and dyslipidemia
OR, 5.07; 95% CI, 1.92 — 13.44).
The 44.45% of patients with dyslipidemia died vs. 20.8%
f patients who did not show such condition (Figure 1). No
igniﬁcant differences were observed in relation to mean
ge (63.8 vs. 68.7) or gender between patients with and
ithout dyslipidemia.
iscussion
ne of the most relevant data obtained in the present study,
nd which contributes to its seriousness and external accu-
acy, is the appropriate two-year follow-up of 97% of the
ample made up only of patients with PE who were conse-
utively and prospectively enrolled in the study.
The sample of patients was homogeneous and its dis-
ribution between genders was similar to that observed in
ther studies13,14. Patient age was similar to that reported
y different series in the United States13, Spain2 and other
uropean studies15—17.
Reported survival rate after VTE varies widely17,18.
uch variability is probably the result of the shortcomings
bserved in study design: patients with negative clini-
al evolution19—21, patients diagnosed in residences15—22,
ge > 65 years15,22, patients admitted to tertiary level
ospitals23,24 or patients from clinical trials25,26. As a result,
n accurate estimate of global survival rate associated to
TE cannot be obtained. Anyway mortality observed in our
tudy is similar to other series2,3.
The factors associated to a lower survival rate men-
ioned in our study had already been analysed in previous
tudies, as in the case of neoplasm, dementia and renal
nsufﬁciency27—29. Dementia is considered a negative prog-
ostic factor in new prognostic scales29,30, but at present
yslipidemia is not included in any scale.
d
e
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High serum cholesterol and LDL cholesterol levels, and
ow HDL cholesterol levels are considered risk factors for
therothrombosis31. Despite their potent effect on athero-
enesis, lipids and lipoproteins could affect haemostasis
y modulating the procoagulant and ﬁbrinolytic expression
nd function32. Doggen et al.9 have shown that elevated
riglycerides levels pose a higher risk (twofold) for venous
hrombosis. A case-control study10 also reported the fact
hat hypercholesterolemia is associated with a higher risk of
VT. As regards hypertriglyceridemia, results are controver-
ial: some studies associate it with venous thrombosis9—12,
ut others do not report such interplay33. It is important to
arry out the measurements prior to the onset of therapy,
ecause it is known that lipid levels diminish in the event
f an acute vascular episode34. Finally, Tsai et al.8, in their
nalysis of cardiovascular risk factors and incidence of a ﬁrst
pisode of VTE, concluded that some arterial risk factors,
ncluding dyslipidemia, were not associated with VTE.
All the above mentioned studies establish the association
f dyslipidemia with a ﬁrst episode of VTE, but we report the
ssociation of dyslipidemia, as an independent risk factor,
ith lower long-term survival rate in patients with PE.
The interplay between dylipidemia and PE in this sense
as not been thoroughly analysed yet. In our series, long-
erm mortality rate due to vascular reasons in patients with
yslipidemia who have suffered PE is sevenfold greater than
ortality in untreated dyslipidemic patients5. Moreover, the
ortality rate observed in our patients with PE is more than
wofold greater in patients with dylipidemia than in those
ithout this condition. We do not know for sure whether
he fact of having suffered an episode of PE boosts the
ffect of dyslipidemia as a prognostic factor for lower sur-
ival. Nor do we know whether patients with dyslipidemia
ho suffer PE are those with a more advanced or difﬁcult
o manage metabolic disease. Other questions we should
nswer would be: which parameters deﬁned as dyslipidemia
re considered more determinant and whether the progno-
is of these patients may improve with statin therapy. This
ast question would have signiﬁcant practical implications as
e already know that statin therapy in dyslipidemic patients
educes mortality in 12.37% a year, disregard of the cause of
eath5.This work has several limitations. Firstly, the sample
f patients included in our study is not large but the results
et at hypothetical new factor related to a poor survival.
urther studies with larger samples and primarily focused
n this issue could answer many of the above mentioned
uestions. Secondly, other data not available and would be
nteresting to contrast with the results obtained are quan-
itative results of total cholesterol, LDL-cholesterol, HDL
holesterol, triglycerides, duplication of tests and if the
nalytical was fasting or not, and whether the patient was
aking statins. Individuals treated with lipid-lowering drugs
hould be excluded or taking into account, because treat-
ent could affect lipid levels. Several studies, including
urs, did not make such exclusion10,35. These data were not
onsidered when designing the study. The development of
rospective studies should collect these data.
We think that this ﬁnding also becomes more important
ue mainly to two recently published papers. Khemasuwan
t al. suggest that the use of statins is associated with a
igniﬁcant reduction in the occurrence of venous throm-
oembolism in patients with cancer36. Glynn et al. in a
y emDyslipidemia as a long-term marker for survival in pulmonar
randomized trial of apparently healthy persons found that
rosuvastatin signiﬁcantly reduced the occurrence of symp-
tomatic venous thromboembolism37. These previous results
in addition to our work open a ﬁeld of research on whether
this type of Venous Thromboembolism patients may beneﬁt
from treatment with statins.
Conclusion
We could summarize that in our study, patients with dyslipi-
demia who suffered PE showed worse survival rate. The role
dyslipidemia may have as a vascular risk factor especially in
patients with PE and the possibility to improve survival rates
warrants further investigation.
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